Ministry of Industry and Information Technology informed these pharmaceutical companies to be named!

According to the publicity content, there are 3 consortiums to be identified as the second batch of small varieties of drugs (shortage drugs) centralized production base construction units, publicity time is November 18, 2019 - November 22, 2019, the list is as follows:, China's drug shortage statusthe current situation of more than 3,200 commonly used drugs, there are more than 200 kinds of large increases, concentrated in part of the shortage, emergency (snatching) drug and a small number of prescription drugs and other prescription drugsit has been reported that chlorarazzimen, which are used in multidrug-resistant TB treatment, have been out of stock for more than a year, affecting at least 20,000 patients, and news of the out-of-stock drug, a common drug for blood tumours, has been running out of supply worldwide since January 2019Starting in early 2019, commonly used drugs such as nitric acid and glycerin have been out of stockwe can find that many of the shortages are often cheap and commonly used medicinesThese drugs are low-cost, accurate efficacy, in the primary medical institutions and the vast number of patients have a reputationSuch as nitrobenzene, puritanol, syddland and so onHowever, these good and cheap common lying drugs, in recent years, there have been repeated shortages, price increases, production stoppagesshortage scarcity or out-of-stock of cheap and commonly used medicines is due to a variety of factorsproduction level, some raw materials supply seasonal is relatively strong, or the market concentration is easy to be controlled, or some of the drug market capacity is small, clinical demand is not large but irreplaceable, or some drugs production technology threshold is relatively high, in the short term other enterprises difficult to involvemarket level, the profit margin of cheap drugs is small, commercial companies, distribution enterprises generally do not value these varietiesIn addition, many cheap drugs are raw materials and production costs have risen, further reducing their profit marginsthe main problem, or out of the cheap, because of the profit margin is small, the whole link of the practitioners are not high enthusiasmthese pharmaceutical companies, in the actionin addition to the above-mentioned publicity of the three consortiums, on January 28 this year, the Ministry of Industry and Information Technology has announced the first batch of small varieties of drugs (shortage drugs) centralized production base construction units listThe first three bases of the are: Shanghai Pharmaceutical Group Co., Ltd led by the formation of the consortium, by the Shanghai Pharmaceutical Xinyi Pharmaceutical Co., Ltd jointly 23 enterprise organizations, China Pharmaceutical Group Co., Ltd led by the formation of the consortium, by Shanghai Hyundai Pharmaceutical Co., Ltd., China Biotechnology Co., Ltd organized by the consortium, led by Chengdu Perteo Pharmaceutical Co., Ltd., by Chengdu Perte Pharmaceutical Co., Ltd jointchongqing chongqing Pharmaceutical Co., Ltd and other 9 enterprise organizations Ministry of Industry and Information Technology, the former State Health and Planning Commission, the National Development and Reform Commission, the former State Administration of Food and Drug Administration on February 1, 2018 jointly issued "on the organization of small varieties of drugs (shortage drugs) centralized production base construction notice", clearly mentioned that small varieties of drugs (shortage drugs) refers to clinical necessity, small dosage, market supply instability, prone to clinical shortage of drugs notice, will adhere to the market-led, government-led, innovative mechanism, classification and implementation of the principle, fully mobilize the initiative of enterprises, integration of existing industrial resources, play a concentrated production scale effect, to ensure the sustainable and stable supply of small varieties of drugs Through coordinated solutions to the problems of small-variety drug code transfer, commissioned production, centralized procurement, supply and demand docking, support enterprises to concentrate high-quality resources upstream and downstream of the industrial chain, promote the implementation of the target task of centralized production base construction, by 2020, will basically achieve the centralized production and stable supply of 100 kinds of small varieties of drugs with the gradual establishment of the supply guarantee system for the shortage of medicines, the contradiction of shortage of medicines has been alleviated, the large-scale, long-term shortage has been greatly reduced, mainly there is still a short-term, local shortage In the era of big data, it is particularly important to build a digital early warning system which is easy to develop, produce and circulate drugs The linkage between the government and the market, the linkage of the downstream industrial chain in the market, can completely solve and prevent the shortage of medicines.